ZGT
Welcome,         Profile    Billing    Logout  
 10 Trials 
10 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Oosterkamp, Rianne
Triple-B, NCT01898117 / 2013-001484-23: Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer

Active, not recruiting
2
304
Europe
Carbo/cyclo, Carboplatin, Cyclophosphamide, Carbo/cyclo + atezolizumab, Atezolizumab, Paclitaxel, Paclitaxel + Atezolizumab
The Netherlands Cancer Institute, Borstkanker Onderzoek Groep, Roche Pharma AG
Breast Cancer
12/24
12/30
Oving, I M
Triple-B, NCT01898117 / 2013-001484-23: Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer

Active, not recruiting
2
304
Europe
Carbo/cyclo, Carboplatin, Cyclophosphamide, Carbo/cyclo + atezolizumab, Atezolizumab, Paclitaxel, Paclitaxel + Atezolizumab
The Netherlands Cancer Institute, Borstkanker Onderzoek Groep, Roche Pharma AG
Breast Cancer
12/24
12/30
Holzik, Martijn Lutke
A1Check, NCT05810207: the External Validation of a Machine Learning Model Predicting Colorectal Anastomotic Leakage

Recruiting
N/A
1000
Europe
Colorectal resection
Freek Daams, SAS Institute
Anastomotic Leak, Anastomotic Leak Large Intestine, Anastomotic Complication, Anastomotic Leak Rectum
07/24
12/24
Kok, Marleen
TONIC-2, NCT04159818: Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients

Recruiting
2
52
Europe
Nivolumab, Cisplatin, Low dose doxorubicin
The Netherlands Cancer Institute, Bristol-Myers Squibb
Metastatic Breast Cancer
12/22
12/26
MIMOSA, NCT04307329 / 2020-000849-14: Monalizumab and Trastuzumab In Metastatic HER2-pOSitive breAst Cancer: -trial

Completed
2
12
Europe
Monalizumab, Trastuzumab
The Netherlands Cancer Institute, AstraZeneca
Breast Cancer
01/23
03/24
TONIC, NCT02499367 / 2015-001969-49: Nivolumab After Induction Treatment in Triple-negative Breast Cancer (TNBC) Patients

Active, not recruiting
2
84
Europe
Nivolumab, Radiation therapy, Low dose doxorubicin, Cyclophosphamide, Cisplatin
The Netherlands Cancer Institute, Bristol-Myers Squibb
Breast Cancer
12/23
08/25
TONIC-3, NCT06342037: NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: Trial

Recruiting
2
60
Europe
Tiragolumab, Atezolizumab, Tecentriq, Ipilimumab, Yervoy
The Netherlands Cancer Institute, Hoffmann-La Roche
Metastatic Breast Cancer
04/26
04/30
Triple-B, NCT01898117 / 2013-001484-23: Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer

Active, not recruiting
2
304
Europe
Carbo/cyclo, Carboplatin, Cyclophosphamide, Carbo/cyclo + atezolizumab, Atezolizumab, Paclitaxel, Paclitaxel + Atezolizumab
The Netherlands Cancer Institute, Borstkanker Onderzoek Groep, Roche Pharma AG
Breast Cancer
12/24
12/30
ANISE, NCT05982678: Basket Study for Oligo-metastatic Breast Cancer

Recruiting
2
72
Europe
Trastuzumab deruxtecan
The Netherlands Cancer Institute, Daiichi Sankyo, AstraZeneca
HER2-positive Breast Cancer
10/27
10/34
Staal, Jeske
ELDAPT, NCT02284308: Elderly With Locally Advanced Lung Cancer: Deciding Through Geriatric Assessment on the Optimal Treatment Strategy

Active, not recruiting
N/A
180
Europe
Blood withdrawal
Maastricht Radiation Oncology, Dutch Society of Physicians for Pulmonology and Tuberculosis, Erasmus Medical Center, VieCuri Medical Centre, AstraZeneca, Dutch Cancer Society
NSCLC
01/25
12/29

Download Options